Selected research
Market Structure
Global Mumps Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Mumps Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Mumps Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Mumps Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Mumps Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Mumps Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Mumps Drug include GlaxoSmithKline Plc, Beijing Tiantan Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd, Zydus Cadila Healthcare Limited, Sinovac Biotech Ltd., Prometheon Pharma, LLC, Organic Vaccines and China National Pharmaceutical Group Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Mumps Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Mumps Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Mumps Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mumps Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Mumps Drug Segment by Company
GlaxoSmithKline Plc
Beijing Tiantan Biological Products Co., Ltd.
Beijing Minhai Biotechnology Co., Ltd
Zydus Cadila Healthcare Limited
Sinovac Biotech Ltd.
Prometheon Pharma, LLC
Organic Vaccines
China National Pharmaceutical Group Corporation
Mumps Drug Segment by Type
RIT 4385
Wistar RA 27/3
Schwarz
Others
Mumps Drug Segment by Application
Hospital
Clinic
Others
Mumps Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mumps Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mumps Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mumps Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Mumps Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mumps Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Mumps Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Mumps Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- RIT 4385
- Wistar RA 27/3
- Schwarz
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- GlaxoSmithKline Plc
- Beijing Tiantan Biological Products Co., Ltd.
- Beijing Minhai Biotechnology Co., Ltd
- Zydus Cadila Healthcare Limited
- Sinovac Biotech Ltd.
- Prometheon Pharma, LLC
- Organic Vaccines
- China National Pharmaceutical Group Corporation
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Mumps Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Mumps Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Mumps Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Mumps Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Mumps Drug Market Dynamics
- 2.1 Mumps Drug Industry Trends
- 2.2 Mumps Drug Industry Drivers
- 2.3 Mumps Drug Industry Opportunities and Challenges
- 2.4 Mumps Drug Industry Restraints
3 Mumps Drug Market by Manufacturers
- 3.1 Global Mumps Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Mumps Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Mumps Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Mumps Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Mumps Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Mumps Drug Manufacturers, Product Type & Application
- 3.7 Global Mumps Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Mumps Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Mumps Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Mumps Drug Tier 1, Tier 2, and Tier 3
4 Mumps Drug Market by Type
- 4.1 Mumps Drug Type Introduction
- 4.1.1 RIT 4385
- 4.1.2 Wistar RA 27/3
- 4.1.3 Schwarz
- 4.1.4 Others
- 4.2 Global Mumps Drug Sales by Type
- 4.2.1 Global Mumps Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Mumps Drug Sales by Type (2021-2032)
- 4.2.3 Global Mumps Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Mumps Drug Revenue by Type
- 4.3.1 Global Mumps Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Mumps Drug Revenue by Type (2021-2032)
- 4.3.3 Global Mumps Drug Revenue Market Share by Type (2021-2032)
5 Mumps Drug Market by Application
- 5.1 Mumps Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Mumps Drug Sales by Application
- 5.2.1 Global Mumps Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Mumps Drug Sales by Application (2021-2032)
- 5.2.3 Global Mumps Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Mumps Drug Revenue by Application
- 5.3.1 Global Mumps Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Mumps Drug Revenue by Application (2021-2032)
- 5.3.3 Global Mumps Drug Revenue Market Share by Application (2021-2032)
6 Global Mumps Drug Sales by Region
- 6.1 Global Mumps Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Mumps Drug Sales by Region (2021-2032)
- 6.2.1 Global Mumps Drug Sales by Region (2021-2026)
- 6.2.2 Global Mumps Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Mumps Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Mumps Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Mumps Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Mumps Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Mumps Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Mumps Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Mumps Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Mumps Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Mumps Drug Revenue by Region
- 7.1 Global Mumps Drug Revenue by Region
- 7.1.1 Global Mumps Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Mumps Drug Revenue by Region (2021-2026)
- 7.1.3 Global Mumps Drug Revenue by Region (2027-2032)
- 7.1.4 Global Mumps Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Mumps Drug Revenue (2021-2032)
- 7.2.2 North America Mumps Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Mumps Drug Revenue (2021-2032)
- 7.3.2 Europe Mumps Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Mumps Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Mumps Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Mumps Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Mumps Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 GlaxoSmithKline Plc
- 8.1.1 GlaxoSmithKline Plc Company Information
- 8.1.2 GlaxoSmithKline Plc Business Overview
- 8.1.3 GlaxoSmithKline Plc Mumps Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 GlaxoSmithKline Plc Mumps Drug Product Portfolio
- 8.1.5 GlaxoSmithKline Plc Recent Developments
- 8.2 Beijing Tiantan Biological Products Co., Ltd.
- 8.2.1 Beijing Tiantan Biological Products Co., Ltd. Company Information
- 8.2.2 Beijing Tiantan Biological Products Co., Ltd. Business Overview
- 8.2.3 Beijing Tiantan Biological Products Co., Ltd. Mumps Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Beijing Tiantan Biological Products Co., Ltd. Mumps Drug Product Portfolio
- 8.2.5 Beijing Tiantan Biological Products Co., Ltd. Recent Developments
- 8.3 Beijing Minhai Biotechnology Co., Ltd
- 8.3.1 Beijing Minhai Biotechnology Co., Ltd Company Information
- 8.3.2 Beijing Minhai Biotechnology Co., Ltd Business Overview
- 8.3.3 Beijing Minhai Biotechnology Co., Ltd Mumps Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Beijing Minhai Biotechnology Co., Ltd Mumps Drug Product Portfolio
- 8.3.5 Beijing Minhai Biotechnology Co., Ltd Recent Developments
- 8.4 Zydus Cadila Healthcare Limited
- 8.4.1 Zydus Cadila Healthcare Limited Company Information
- 8.4.2 Zydus Cadila Healthcare Limited Business Overview
- 8.4.3 Zydus Cadila Healthcare Limited Mumps Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Zydus Cadila Healthcare Limited Mumps Drug Product Portfolio
- 8.4.5 Zydus Cadila Healthcare Limited Recent Developments
- 8.5 Sinovac Biotech Ltd.
- 8.5.1 Sinovac Biotech Ltd. Company Information
- 8.5.2 Sinovac Biotech Ltd. Business Overview
- 8.5.3 Sinovac Biotech Ltd. Mumps Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Sinovac Biotech Ltd. Mumps Drug Product Portfolio
- 8.5.5 Sinovac Biotech Ltd. Recent Developments
- 8.6 Prometheon Pharma, LLC
- 8.6.1 Prometheon Pharma, LLC Company Information
- 8.6.2 Prometheon Pharma, LLC Business Overview
- 8.6.3 Prometheon Pharma, LLC Mumps Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Prometheon Pharma, LLC Mumps Drug Product Portfolio
- 8.6.5 Prometheon Pharma, LLC Recent Developments
- 8.7 Organic Vaccines
- 8.7.1 Organic Vaccines Company Information
- 8.7.2 Organic Vaccines Business Overview
- 8.7.3 Organic Vaccines Mumps Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Organic Vaccines Mumps Drug Product Portfolio
- 8.7.5 Organic Vaccines Recent Developments
- 8.8 China National Pharmaceutical Group Corporation
- 8.8.1 China National Pharmaceutical Group Corporation Company Information
- 8.8.2 China National Pharmaceutical Group Corporation Business Overview
- 8.8.3 China National Pharmaceutical Group Corporation Mumps Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 China National Pharmaceutical Group Corporation Mumps Drug Product Portfolio
- 8.8.5 China National Pharmaceutical Group Corporation Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Mumps Drug Value Chain Analysis
- 9.1.1 Mumps Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Mumps Drug Production Mode & Process
- 9.2 Mumps Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Mumps Drug Distributors
- 9.2.3 Mumps Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst